NASDAQ:ALXO ALX Oncology (ALXO) Stock Price, News & Analysis $1.10 -0.03 (-2.92%) As of 03:54 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ALX Oncology Stock (NASDAQ:ALXO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ALX Oncology alerts:Sign Up Key Stats Today's Range$1.05▼$1.1650-Day Range$0.89▼$2.0852-Week Range$0.86▼$2.66Volume2.26 million shsAverage Volume1.08 million shsMarket Capitalization$151.69 millionP/E RatioN/ADividend YieldN/APrice Target$4.60Consensus RatingModerate Buy Company Overview ALX Oncology Holdings Inc. (NASDAQ: ALXO) is a clinical-stage biopharmaceutical company focused on developing immunotherapies for the treatment of cancer. The company’s research centers on the CD47-SIRPα pathway, an immune checkpoint that cancer cells can use to evade detection and destruction by the immune system. ALX Oncology’s lead product candidate is evorpacept, also known as ALX148, an investigational protein designed to block CD47 while supporting the activity of therapeutic antibodies and other anti-cancer treatments. The company has evaluated evorpacept in combination with established cancer therapies, including targeted antibodies, immune checkpoint inhibitors and chemotherapy, across multiple solid-tumor and blood-cancer settings. Founded in 2015 and headquartered in South San Francisco, California, ALX Oncology conducts clinical development through collaborations and studies involving research and treatment centers in the United States and other regions. Its programs remain investigational and have not been established as safe or effective for any particular use by regulatory authorities.AI Generated. May Contain Errors. Read More ALX Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreALXO MarketRank™: 3.07642654273 of 5 starsALX Oncology scored higher than 62% of companies evaluated by MarketBeat, and ranked 375th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingALX Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialALX Oncology has a consensus price target of $4.60, representing about 316.3% upside from its current price of $1.11.Amount of Analyst CoverageALX Oncology has only been the subject of 1 research reports in the past 90 days.Read more about ALX Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ALX Oncology are expected to decrease in the coming year, from ($0.59) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ALX Oncology is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ALX Oncology is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioALX Oncology has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ALX Oncology's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.93% of the float of ALX Oncology has been sold short.Short Interest Ratio / Days to CoverALX Oncology has a short interest ratio ("days to cover") of 3.63, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ALX Oncology has recently increased by 5.35%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldALX Oncology does not currently pay a dividend.Dividend GrowthALX Oncology does not have a long track record of dividend growth. News and Social Media4.0 / 5News Sentiment1.33 News SentimentALX Oncology has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ALX Oncology this week, compared to 3 articles on an average week.Search Interest2 people have searched for ALXO on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added ALX Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ALX Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,410.00 in company stock.Percentage Held by Insiders12.40% of the stock of ALX Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.97% of the stock of ALX Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ALX Oncology's insider trading history. Receive ALXO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALXO Stock News HeadlinesALX Oncology (NASDAQ:ALXO) Shares Down 3.4% - Here's WhyOctober 27 at 2:01 AM | americanbankingnews.comAnalysts Are Bullish on These Healthcare Stocks: ALX Oncology Holdings (ALXO), United Therapeutics (UTHR)October 21, 2026 | theglobeandmail.comWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.October 27 at 1:00 AM | Digest Publishing (Ad)Alx Oncology Holdings (ALXO)September 30, 2026 | in.investing.comALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2 ...September 28, 2026 | finance.yahoo.comAlx Oncology Holdings Inc. Announces Nature Medicine Publication of Aspen-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept ...September 28, 2026 | marketscreener.comMALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric CancerSeptember 28, 2026 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: ALX Oncology Holdings (ALXO), Tonix Pharma (TNXP)September 22, 2026 | theglobeandmail.comSee More Headlines ALXO Stock Analysis - Frequently Asked Questions How have ALXO shares performed this year? ALX Oncology's stock was trading at $1.13 at the start of the year. Since then, ALXO stock has decreased by 2.2% and is now trading at $1.1050. How were ALX Oncology's earnings last quarter? ALX Oncology Holdings Inc. (NASDAQ:ALXO) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.01. When did ALX Oncology IPO? ALX Oncology (ALXO) raised $136 million in an IPO on Friday, July 17th 2020. The company issued 8,500,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor served as the underwriters for the IPO and LifeSci Capital was co-manager. How do I buy shares of ALX Oncology? Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ALX Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ALX Oncology investors own include Atai Beckley (ATAI), Definium Therapeutics (DFTX), Nkarta (NKTX), Palantir Technologies (PLTR), MP Materials (MP), Aclaris Therapeutics (ACRS) and Annexon (ANNX). Company Calendar Last Earnings8/06/2026Today10/27/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 6 days, ALXO's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALXO CIK1810182 Webwww.alxoncology.com Phone650-466-7125FaxN/AEmployees48Year Founded2015Price Target and Rating Average Price Target for ALX Oncology$4.60 High Price Target$6.00 Low Price Target$4.00 Potential Upside/Downside+317.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$101.69 million Net MarginsN/A Pretax MarginN/A Return on Equity-90.30% Return on Assets-67.28% Debt Debt-to-Equity Ratio0.07 Current Ratio9.71 Quick Ratio9.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book2.30Miscellaneous Outstanding Shares138,280,000Free Float121,131,000Market Cap$152.38 million OptionableOptionable Beta0.47 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:ALXO) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
